Hoffmann-la Roche

This study tests whether adding the drug giredestrant to standard treatment (Phesgo) can help people with advanced HER2-positive, estrogen receptor-positive breast cancer live longer without their cancer getting worse. About 922 participants who have not had prior treatment for a…

This study aimed to see if adding the targeted drug inavolisib to standard chemotherapy and bevacizumab could help people with a specific genetic form of advanced colorectal cancer (PIK3CA-mutated). It was designed for adults who had not yet received treatment for metastatic dise…

This study tests whether a higher dose of the drug ocrelizumab can better control relapsing multiple sclerosis (MS) and delay disability compared to the standard dose. About 864 adults with relapsing MS will receive either the higher or standard dose every 24 weeks. The main goal…

This study tests a new drug called glofitamab added to standard chemotherapy (R-CHOP) for people with a fast-growing type of lymphoma that has a high risk of coming back. The goal is to see if the combination is safe and helps more patients achieve complete remission. About 46 ad…

This study offers continued access to the cancer drug atezolizumab for patients who were already benefiting from it in a previous Roche-sponsored trial. Around 1,000 participants who cannot get the drug locally can keep receiving it. The main goal is to provide ongoing treatment …

This study tests a new experimental drug, englumafusp alfa, combined with two other drugs (obinutuzumab and glofitamab) in people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to prior treatments. The goal is to see if the combination is safe and can shrin…

This study tests whether adding an experimental drug (RO7204239) to an existing SMA treatment (risdiplam) can help muscles grow stronger. It involves about 259 children and young adults with spinal muscular atrophy who can walk. The goal is to see if the combination is safe and i…

This study tests different treatments for people with stage III non-small cell lung cancer that cannot be removed by surgery. Participants are grouped by specific genetic markers (biomarkers) to see which therapy works best for their cancer type. The main goal is to see how long …

This study tests a new medicine called crovalimab against the current standard treatment, eculizumab, in about 190 people with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare blood disorder that can cause fatigue, blood clots, and other serious problems. The goal is to s…

This study gives continued access to the cancer drug pertuzumab for people with solid tumors who were already benefiting from it in an earlier Roche-sponsored trial. About 154 participants will receive the drug until their disease worsens or side effects become unacceptable. The …

This study tests several targeted therapies for people with advanced or metastatic non-small cell lung cancer. Researchers use a simple blood test to find specific genetic changes in the cancer, then match patients to a treatment that targets those changes. The goal is to shrink …

This early-stage study tests a new drug, zifibancimig, for people with wet age-related macular degeneration (nAMD), a leading cause of vision loss. The drug is given either as an eye injection or through a small implant that releases it continuously. The goal is to see if it is s…

This study tests a newer drug, alectinib, against an older one, crizotinib, in Asian patients with a specific type of advanced lung cancer (ALK-positive). The goal is to see which drug better delays cancer growth. About 187 patients took one of the two pills twice daily. This is …

This study tests whether crovalimab works as well as eculizumab for people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. About 210 adults who have not had prior complement inhibitor therapy will receive either drug. The main goals are to see if crovalimab…

This study tests whether adding atezolizumab to standard drugs (lenvatinib or sorafenib) helps people with advanced liver cancer live longer. It includes 557 adults whose cancer worsened after initial treatment. The goal is to see if the combination improves survival and slows tu…

This study tests a medicine called emicizumab in people aged 13 to 69 with moderate or severe hemophilia A. The goal is to see if it improves joint health, physical activity, and overall well-being. Participants take the medicine regularly to control bleeding and prevent joint da…

This early-stage study tests an experimental drug called RO7790121 in 50 adults with advanced liver scarring (stage F3 or F4) caused by MASH, a fatty liver disease. The main goal is to see if the drug is safe and how it moves through the body. Researchers will also check if it ca…

This study tests a new medicine called crovalimab for people with a rare disease called atypical hemolytic uremic syndrome (aHUS), which causes blood clots and kidney damage. The trial includes 83 adults and teens who receive the drug to see if it can control the disease and impr…

This study compares a new drug, tobemstomig, combined with chemotherapy against the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if the new combination works better a…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This study tests whether combining newer immune-boosting drugs with a standard targeted therapy can safely treat advanced kidney cancer that has spread. About 200 adults with untreated clear-cell renal cell carcinoma will receive either a standard combination or one of two experi…

This study tests whether ocrelizumab is safer and more effective than fingolimod for children and adolescents (ages 10 to under 18) with relapsing-remitting multiple sclerosis. Participants receive either drug and are monitored for relapses and brain lesions over at least 24 week…

This study tests a new medicine called RO7790121 for people with moderate to severe ulcerative colitis, a condition that causes inflammation and sores in the colon. About 400 adults who have not responded well to other treatments will receive either the study drug or a placebo. T…

This study tests whether adding two drugs (atezolizumab and bevacizumab) after liver cancer surgery or ablation can delay or prevent the cancer from coming back. About 668 people with a high risk of recurrence will be randomly assigned to receive the drug combination or just be w…

This study tests a refillable eye implant (Port Delivery System) that slowly releases medication to treat wet age-related macular degeneration, a leading cause of vision loss. About 451 adults aged 50 and older who have already responded to standard injections will receive refill…

This study compares a daily targeted therapy pill (alectinib) with standard chemotherapy in people with ALK-positive non-small cell lung cancer whose tumor was completely removed by surgery. About 257 adults with stage IB to IIIA cancer will take either alectinib for 2 years or c…

This study tests a combination of drugs (glofitamab, atezolizumab, or polatuzumab vedotin, plus a pre-treatment dose of obinutuzumab) in adults with B-cell non-Hodgkin's lymphoma that has come back or not responded to prior treatments. The goal is to find the safest dose and see …

This early-stage study tests an experimental drug called RO7567132, alone or with another drug (atezolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shr…

This study tests the drug ocrelizumab in 927 adults with progressive multiple sclerosis (MS), a condition that steadily worsens over time. The goal is to see if the drug can slow or stop disability progression, reduce relapses, and control brain lesions over 4 years. Participants…

This early-phase study tests the safety of an experimental drug called RO7669330, given as an eye injection, for people with geographic atrophy (a late stage of dry age-related macular degeneration). The study involves 27 participants and will monitor for side effects and how the…

This phase 3 study tests whether a combination of two targeted drugs (mosunetuzumab and polatuzumab vedotin) works better than a standard chemotherapy regimen for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to prior therapy. About 208 adu…

This study aimed to test if crovalimab, added to standard blood thinners, could prevent dangerous blood clots in people with antiphospholipid syndrome (APS). APS is an autoimmune disease that increases clot risk. The trial was withdrawn before enrolling any participants, so no re…

This study tests an experimental drug called RO7790121 in about 21 adults with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can reduce gut inflammation and improve symptoms like diarrhea and stomach pain. Partic…

This study tests a new drug called RO7507062 in 70 people with systemic lupus erythematosus (SLE). The main goal is to check its safety and find the right dose. The study has two parts: one where participants get a single dose, and another where the dose is split over time. This …

This study tests an experimental drug called RO7126209 in people with early or mild-to-moderate Alzheimer's disease who have amyloid plaques in their brain. The main goals are to check the drug's safety and see if it can reduce amyloid buildup. About 241 participants will receive…

This study compares a new drug, fenebrutinib, to an approved medication (teriflunomide) in 751 adults with relapsing multiple sclerosis. The goal is to see if fenebrutinib better reduces relapse rates and delays disability progression. Participants take one of the two pills daily…

This study tests whether fenebrutinib can reduce brain damage in people with relapsing multiple sclerosis (MS). About 109 participants will receive either the drug or a placebo, and brain scans will be used to measure new lesions over 12 weeks. The goal is to see if fenebrutinib …

This study compares two treatments for primary progressive multiple sclerosis (PPMS), a form of MS that steadily worsens over time. About 985 adults with PPMS will receive either a daily pill called fenebrutinib or an infusion of ocrelizumab, the current standard therapy. The goa…

This study tests a new drug called divarasib against two existing drugs (sotorasib and adagrasib) for people with a specific type of advanced lung cancer (KRAS G12C). About 338 participants who have already tried other treatments will be randomly assigned to receive divarasib or …

This study follows about 1,300 people with multiple sclerosis who are already taking ocrelizumab to see how safe and effective it is over the long term. Participants continue their treatment and are checked for side effects, disability changes, and brain scans. The goal is to und…

This study tests whether satralizumab can prevent relapses in people with MOGAD, a rare autoimmune disease that attacks the brain and spinal cord. About 152 participants aged 12 and older will receive either the drug or a placebo, and those who relapse or complete the main study …

This study tests a daily pill called giredestrant in 30 people with Grade 1 endometrial cancer. The goal is to see if the drug can shrink the cancer or keep it from growing over 6 months, possibly avoiding or delaying surgery. Participants take the drug for 6 months and have regu…

This study tests an experimental drug called RO7204239 in 51 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic disease that causes progressive muscle weakness. The drug is designed to block a protein that limits muscle growth, with the goal of preserving or imp…

This study tests a drug called crovalimab in about 50 people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease that destroys red blood cells. Participants must be at least 12 years old, weigh 40 kg or more, and have not received prior complement inhibitor treat…

This study tests whether adding the targeted drug alectinib to standard chemotherapy is safe for people with a specific type of lung cancer (ALK-positive non-small cell) after they have had surgery to remove the tumor. The 11 participants receive up to four cycles of the combinat…

This study tests an experimental drug called tominersen in 301 people with early Huntington's disease. The goal is to see if it is safe and can slow the disease by lowering a harmful protein in the brain. Participants receive either the drug or a placebo, and researchers monitor …

This study tests a new drug, crovalimab, in healthy volunteers and people with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease that destroys red blood cells. The goal is to see if the drug is safe and can control the disease by blocking part of the immune system. …

This study tests a once-daily pill called RO7795081 for helping people with obesity or overweight who also have weight-related health problems (like high blood pressure) lose weight. About 352 adults will take either the drug or a placebo for 38 weeks. The main goal is to see how…

This study tests an experimental drug called cevostamab in about 90 people whose multiple myeloma has returned or stopped responding to other treatments, including prior BCMA-targeted therapies. The goal is to see if the drug can shrink tumors and control the cancer, while monito…

This study tested an oral medicine called risdiplam in 26 babies who have a genetic diagnosis of spinal muscular atrophy (SMA) but no symptoms yet. The goal was to see if starting treatment early helps them reach key motor milestones, like sitting without support. The babies were…

This study tests a drug called satralizumab in 30 children aged 8 to 17 with Duchenne muscular dystrophy (DMD). The goal is to see if it can improve bone density and slow muscle decline. Participants continue their usual steroid treatment while receiving the study drug.

This study tests the safety and dosing of ocrelizumab in 23 children and teens (ages 10–18) with relapsing-remitting multiple sclerosis over 2 years. The goal is to find the best dose for a future larger study. Participants receive the drug and are monitored for side effects and …

This study tests an experimental drug called prasinezumab in 316 people with early Parkinson's disease. The drug is an antibody designed to target and remove clumps of a protein linked to Parkinson's. Participants receive either the drug or a placebo for 52 weeks, with an option …

This study tests whether adding the experimental drug glofitamab to standard chemotherapy (gemcitabine plus oxaliplatin) helps people with relapsed or refractory diffuse large B-cell lymphoma live longer compared to the current standard treatment (rituximab plus the same chemo). …

This study tests a new drug called glofitamab, alone or with another drug (obinutuzumab), in people with B-cell non-Hodgkin's lymphoma that has come back or not responded to previous treatments. The goal is to find the safest and most effective dose and see how well it shrinks tu…

This study tests whether a newer targeted drug, entrectinib, works better than the current standard drug, crizotinib, for people with advanced lung cancer that has a specific genetic change (ROS1). About 220 participants will take one of the two pills daily. The study focuses on …

This study tests whether faricimab, an eye injection, can be given as infrequently as every 24 weeks to people with wet age-related macular degeneration (nAMD) who have not been treated before. The goal is to see if it keeps vision stable and reduces the need for more frequent sh…

This study tests whether adding the immunotherapy drug atezolizumab to the targeted therapy trastuzumab emtansine (T-DM1) can help prevent breast cancer from returning in people with HER2-positive breast cancer who still have cancer cells after initial treatment and surgery. Abou…

This study tests several targeted treatments for people with rare ovarian cancers that have come back or not gone away. Researchers choose the treatment based on specific markers found in each person's tumor. The goal is to see if these drugs can shrink or control the cancer. Abo…

This study tests two new drug combinations (tobemstomig alone or with tiragolumab) against an existing drug (atezolizumab) in 204 people with advanced bladder cancer who cannot receive standard platinum chemotherapy. The goal is to see if the new treatments are safer and help con…

This study tests whether adding a new drug called tiragolumab to a standard two-drug combination (atezolizumab and bevacizumab) helps people with advanced liver cancer that cannot be removed by surgery. About 687 participants will receive either the three-drug combo or the two-dr…

This study tests a new daily medication, fenebrutinib, against an existing drug (teriflunomide) in about 746 adults with relapsing multiple sclerosis. The goal is to see if fenebrutinib better reduces relapse rates and delays worsening disability. Participants take either drug fo…

This study tests a drug called satralizumab in 127 people with moderate-to-severe thyroid eye disease, a condition that causes eye bulging and discomfort. Participants receive either the drug or a placebo to see if it reduces eye bulging by at least 2 millimeters over 24 weeks. T…

This study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…

This study tests whether the drug atezolizumab can help prevent non-small cell lung cancer from coming back after surgery and chemotherapy. About 1,280 people with stage IB to IIIA lung cancer took part. Half received atezolizumab for about a year, and half received standard moni…

This study tests a new medicine called Afimkibart (RO7790121) for people with moderate to severe eczema (atopic dermatitis). About 160 adults will receive either the drug or a placebo to see if it improves skin symptoms like redness and itching. The main goal is to measure at lea…

This study tests a new treatment called OpRegen, made from stem cells, for people with advanced dry age-related macular degeneration (AMD). The cells are placed under the retina to replace damaged cells and slow disease progression. The trial involves 24 adults aged 50 and older …

This study tests whether a higher dose of the drug ocrelizumab can better slow disability progression in people with primary progressive multiple sclerosis (PPMS). About 769 adults with PPMS will receive either the approved dose or a higher dose every 24 weeks. The main goal is t…

This study tests an experimental drug called prasinezumab in 586 people with early Parkinson's disease who are already on standard medication. The goal is to see if the drug can delay worsening of motor symptoms like tremor and stiffness. Participants receive either the drug or a…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy and trastuzumab can improve outcomes for people with HER2-positive stomach or gastroesophageal junction cancer that can be surgically removed. About 42 participants will receive either th…

This early-phase study tests a drug called inavolisib, alone or with atezolizumab, in people with cancers that have a specific change in the PIK3CA gene. The study includes patients with head and neck cancer that has returned or spread. The main goals are to check safety and see …

This study tests a drug called entrectinib in people with advanced cancers that have certain gene changes (NTRK, ROS1, or ALK). About 534 adults with 15 different cancer types will take the pill daily. The goal is to see if the drug shrinks tumors and how long that effect lasts.

This study tests whether ocrelizumab (Ocrevus) can slow disability worsening in adults with primary progressive multiple sclerosis (PPMS), including those with more advanced disease. About 1,000 participants receive either the drug or a placebo, and researchers measure changes in…

This study tests a drug called obinutuzumab in 303 people with active lupus. Participants receive either the drug or a placebo, along with their usual treatments. The goal is to see if obinutuzumab can reduce lupus symptoms and disease activity better than placebo alone.

This study tests a drug called atezolizumab in 60 people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. Participants have not received prior treatment for their advanced cancer. The goal is to see if the drug helps them live longer and co…

This study tests a new drug combination (inavolisib plus fulvestrant) against an existing one (alpelisib plus fulvestrant) in people with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that has worsened despite prior treatment. About 420 participan…

This study follows over 2,700 people with bladder, lung, or liver cancer who are receiving the drug atezolizumab as part of their normal treatment. Researchers are tracking how long patients live and how well the drug controls their cancer outside of a controlled clinical trial. …

This study follows 800 people with ALK-positive advanced non-small cell lung cancer who are taking alectinib as part of their routine care. Researchers are collecting data on how long the treatment controls the cancer, survival rates, and what treatments are used next. The goal i…

This study is observing 6,000 adults already receiving Roche eye treatments for conditions like wet macular degeneration and diabetic eye swelling. Researchers will collect real-world data over several years to see how well the drugs work and how they are used in routine care. No…

This study looks at how breast cancer is diagnosed and treated in Latin America. Researchers will follow about 2,900 newly diagnosed patients to understand different cancer types, treatments used, and health outcomes. The goal is to gather information that can help improve care f…

This study follows 1,000 Chinese adults with diffuse large B-cell lymphoma (a fast-growing blood cancer) who are receiving polatuzumab as part of their routine care. Researchers are tracking how long patients stay cancer-free after treatment and noting any side effects. The goal …